Everest Group Life Sciences Digital Services Specialists PEAK Matrix® Assessment 2024

The rapid spread of COVID 19 has resulted in pharma companies facing significant ramifications on their business, requiring a change in assumptions, thinking, and decisions going forward. One such critical area of effect from the pandemic is on incentive compensation (IC). Pharma company investment in the sales force is significant in both personnel and economic terms. Mandates on social ...

Axtria periodically receives questions from pharma clients on whether they should proceed with conducting a sales contest (under the general category of special incentive programs or SIPs), and if so, how should a successful sales contest be designed in order to achieve desired outcomes? Companies annually spend an enormous amount of money on sales contests according to recent estimates. Yet, ...

The short answer to this question is most definitely “yes,” and probably more important now than ever before. Annual pharma company spending on their sales force is still among the single largest line item in the budget, and according to promotion-response and marketing-mix analyses, remains a significant driver of sales revenue and contribution. The changes in the pharma environment from a ...

Companies spend between 10% and 40% of their total revenue on their sales force - Bain, Frontline of Healthcare Report Over 70% organizations feel their employees do not understand the compensation philosophy - workatwork.org Incentive Compensation (IC) can single-handedly make or break your sales force. It’s a process that sales and commercial leaders constantly strive to get right and implement ...

Sales Crediting – a challenge most companies feel today with the increasing complexity of the market! Even more complex is the task of deciphering the downstream impact on incentive compensation and further impact on the sales reps’ motivation because of false crediting. With this whitepaper, unravel the means of actual and correct sales crediting and therefore, reduce pitfalls in incentive ...

Access to Healthcare Practitioners (HCPs) continues to be restricted in this ever-evolving healthcare ecosystem. Contact with stakeholders is typically limited due to stringent anti-rep policies and their organization’s rules and guidelines. This calls for new ways to reach these stakeholders and the evolution of pharmaceutical call planning. This white paper explores the factors used to develop ...

The concept of “all marketing is local” in the pharma environment is more valid today than ever before. We see tremendous variations in salient factors that would affect commercial outcomes from sales and marketing promotion-response and optimization modeling at a subnational level. Data has become more available at the physician, patient, and healthcare system levels allowing for more precise ...

Effective roster management has long been an overlooked topic in Pharma commercial operations. At any point in time, it is critical for the Sales Operations business processes to have access to the latest and distinct set of sales personnel that will need to be accounted for. All functions of commercial operations including sales force sizing, alignment management, call planning, and incentive ...

The healthcare landscape has changed. The traditional way of aligning sales teams is no longer effective. To remain competitive, organizations must deploy sophisticated go-to-market models where talent structures are aligned to engage new stakeholders across multiple channels, regions, specialities and organization size. The impact of inefficient territory alignment is significant: compared to ...